Literature DB >> 32622143

Characterizing dupilumab facial redness in children and adolescents: A single-institution retrospective chart review.

Sonal Muzumdar1, Micaella Zubkov1, Reid Waldman2, Madeline E DeWane3, Rong Wu4, Jane M Grant-Kels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32622143     DOI： 10.1016/j.jaad.2020.06.1003

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.

Authors:  Andrew Alexis; Marjolein de Bruin-Weller; Stephan Weidinger; Weily Soong; Sebastien Barbarot; Ileana Ionita; Fan Zhang; Hernan Valdez; Claire Clibborn; Natalie Yin
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-17

2.  Dupilumab-Associated Head and Neck Dermatitis With Ocular Involvement in a Ten-Year-Old With Atopic Dermatitis: A Case Report and Review of the Literature.

Authors:  Arthur M Samia; Lyda Cuervo-Pardo; Marjorie E Montanez-Wiscovich; Vanessa Y Cavero-Chavez
Journal:  Cureus       Date:  2022-07-23

3.  Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.

Authors:  Ellen Q Wang; Vu Le; Jennifer A Winton; Sakambari Tripathy; Sangeeta Raje; Lisy Wang; Martin E Dowty; Bimal K Malhotra
Journal:  J Clin Pharmacol       Date:  2022-02-15       Impact factor: 2.860

4.  Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study.

Authors:  Emily Kozera; Thomas Stewart; Kyra Gill; Mae Anne De La Vega; John W Frew
Journal:  Br J Dermatol       Date:  2022-04-19       Impact factor: 11.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.